Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977592 | 1.00 | PDE4B (0.49) | PDE4BREN | |
| SCHEMBL4103563 | 0.91 | PDE4B (0.46) | PDE4BREN | |
| SCHEMBL4103566 | 0.91 | PDE4B (0.46) | PDE4BREN | |
| SCHEMBL4301624 | 0.90 | PDE4B (0.46) | PDE4BREN | |
| SCHEMBL4301627 | 0.90 | PDE4B (0.46) | PDE4BREN | |
| SCHEMBL4112225 | 0.90 | PDE4B (0.46) | PDE4BREN | |
| SCHEMBL4300435 | 0.90 | PDE4B (0.46) | PDE4BREN | |
| SCHEMBL4301751 | 0.90 | PDE4B (0.46) | PDE4BREN | |
| SCHEMBL4351285 | 0.89 | REN (0.46) | PDE4BREN | |
| SCHEMBL4351288 | 0.89 | REN (0.46) | PDE4BREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281161-A1 | Organic Compounds | MAIBAUM JUERGEN KLAUS | 2009-11-12 | — | — | US | disclosed |
| US-20090281161-A1 | Organic Compounds | MAIBAUM JUERGEN KLAUS | 2009-11-12 | — | — | US | disclosed |
| EP-2054407-A2 | PYROLIDINE DERIVATIVES USEFUL AGAINST DISEASES THAT DEPENDS ON ACTIVITY OF RENIN | Novartis AG (CH) | 2009-05-06 | — | — | EP | disclosed |
| WO-2007144129-A2 | PYRROLIDINE DERIVATIVES USEFUL AGAINST DISEASES THAT DEPENDS ON ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281161-A1 | Organic Compounds | REN, ACE, OTC | PDE4B 619/4885REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.